Protagonist Therapeutics: MIMRYLO Triggers $275 Million in Payments With the Second FDA Approval
Reading Time: 3 minutes
MIMRYLO is the first and only hepcidin mimetic approved for adults with polycythemia vera. The FDA approval triggers payments of $275 million. Additionally, up to $875 million in milestones and up to 29% in global royalties are anticipated. Following ICOTYDE, MIMRYLO is already the second FDA approval in 2026, strengthening the model of partnership financing, royalties, and its own pipeline. Protagonist Therapeutics (PTGX) develops peptide-based medicines and relies on large pharmaceutical partners for the commercialization...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
